StreetAlpha.app
Home › Stocks › LEXX

Lexaria Bioscience Corp. (LEXX)

$4.03
▼ −10.24%
LAST CLOSE · NOV 20

Lexaria Bioscience licenses DehydraTECH, a technology that improves how active ingredients are absorbed, to drug and consumer product makers. It last closed at $4.03 on Nov 20, down 10.24% on the day. For the quarter ended May 2026, LEXX reported EPS of -$0.08 on revenue of $0, with revenue down 100.0% from a year ago.

AI Auto Pilots
Is LEXX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LEXX.

Key Stats

Last 12 months
Results
Revenue
$194K
−68.5% vs a year ago
Net income
−$7.7M
−3985.6% margin
EPS (diluted)
−$0.34
Free cash flow
−$7.5M
−3848.6% margin
Valuation
Market cap
$99.9M
24.8M shares
P/E
–
No P/E while losing money
Price to sales
514.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.5M
At May 31
Shareholder equity
$4.7M
Shares outstanding
24.8M
At Jul 13
Fiscal year endsAugust
ExchangeNasdaq
Financials history
FY2021: $723K$723KFY2021FY2022: $255K$255KFY2022FY2023: $226K$226KFY2023FY2024: $464K$464KFY2024FY2025: $706K$706KFY2025

From LEXX's SEC filings, latest 10-Q for the period ending May 31, 2026 (filed Jul 13). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.08
Quarter ended May 2026
Year ago EPS
-$0.21
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Aug 2024: -$0.15Aug '24Nov 2024: -$0.16Nov '24Feb 2025: -$0.15Feb '25May 2025: -$0.21May '25Aug 2025: -$0.13Aug '25Nov 2025: -$0.07Nov '25Feb 2026: -$0.06Feb '26May 2026: -$0.08May '26Latest -$0.08
Revenue by quarter
Aug 2024: $84,000Aug '24Nov 2024: $183,923Nov '24Feb 2025: $174,000Feb '25May 2025: $174,000May '25Aug 2025: $174,000Aug '25Nov 2025: $0Nov '25Feb 2026: $20,000Feb '26May 2026: $0May '26Latest $0
StreetAlpha's call on LEXXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Technical Analysis

LEXX · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 109% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 49). The nearest support is the swing low (Nov 17) at $3.96, and the nearest resistance the 20 day average at $4.05.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 11.7%/day
Key levels
$21.6052 week high+436.0%
$8.41200 day average+108.7%
$6.09100 day average+51.1%
$4.79Swing high (Nov 10)+18.9%
$4.35Pivot R1+7.9%
$4.19Pivot+4.0%
$4.0520 day average+0.5%
$4.03Last close
$3.96Swing low (Nov 17)−1.7%
$3.87Pivot S1−4.0%
$3.4850 day average−13.6%
$2.4352 week low−39.7%
Indicators
RSI (14)49.37Middle of its rangeNeutral
MACD0.15Above its signal lineBullish
Stochastic59.3Middle of its rangeNeutral
ADX (14)18.9No clear trend
Williams %R-69.7Oversold below −80, overbought above −20Neutral
CCI (20)28.4Oversold below −100, overbought above 100Neutral
Rate of change−10.4%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 11.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Below
What happened before, for LEXX

What happened before

See how LEXX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LEXX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LEXX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LEXXHow many large options trades hit LEXX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LEXX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼15 buying vs 31 selling
  • ▼Held by funds -5.6 pts
  • ▼Funds holding -16
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1531−51.6%
In funds' top 1000–
Held by funds1.0%6.6%−5.6 pts
New / increased15 / 06 / 90.0%
Reduced / sold out0 / 316 / 3+244.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LEXX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LEXX Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 30, 2025Christopher BunkaDirectorBuy27,500$0.92$25K
Jul 29, 2025Richard ChristopherCEOBuy15,000$0.91$14K
Jul 29, 2025Vanessa CarleSecretaryBuy750$0.91$682
Jul 29, 2025John Martin DochertyPresident & CSOBuy5,376$0.93$5K
Jul 29, 2025William Edward McKechnieDirectorBuy5,000$0.91$5K
Dec 3, 2024Richard ChristopherCEOBuy50,000$2.37$118K
Every insider buy and sale for LEXX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LEXX insider trades →

From SEC Form 4 filings by LEXX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LEXX is in one of them and how their past LEXX trades turned out.

LEXX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LEXX in an article yet. Here's the latest on the wider market.

About Lexaria Bioscience

Lexaria Bioscience is a biotechnology company based in Kelowna, British Columbia, Canada. It develops DehydraTECH, a technology that combines active ingredients with certain fatty acid rich oils so the body absorbs them more effectively. The technology can be used in tablets, capsules, oral suspensions, beverages and oral pouches. Lexaria licenses DehydraTECH to drug, nutraceutical and consumer product makers, who build it into their own products.

Headquarters
Kelowna, British Columbia, Canada